Lantheus (NASDAQ:LNTH) was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Tuesday.

Several other analysts have also weighed in on the company. ValuEngine lowered Lantheus from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Zacks Investment Research lowered Lantheus from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 9th. Jefferies Group upped their target price on Lantheus from $22.00 to $27.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Credit Suisse Group upped their target price on Lantheus from $19.00 to $23.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Finally, Wells Fargo & Company raised Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday, November 2nd. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $24.50.

Lantheus (LNTH) opened at $20.85 on Tuesday. The stock has a market capitalization of $765.12, a price-to-earnings ratio of 18.21, a price-to-earnings-growth ratio of 1.62 and a beta of 0.94. The company has a debt-to-equity ratio of -3.41, a current ratio of 2.96 and a quick ratio of 2.46. Lantheus has a 52-week low of $7.95 and a 52-week high of $24.10.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.04. The firm had revenue of $79.94 million during the quarter, compared to analysts’ expectations of $77.18 million. Lantheus had a negative return on equity of 46.45% and a net margin of 9.59%. Lantheus’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.15 earnings per share. equities analysts expect that Lantheus will post 1.05 EPS for the current fiscal year.

In related news, SVP Timothy G. Healey sold 11,314 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $21.51, for a total transaction of $243,364.14. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Michael P. Duffy sold 20,000 shares of the stock in a transaction on Monday, September 11th. The shares were sold at an average price of $16.45, for a total value of $329,000.00. Following the sale, the insider now directly owns 184,218 shares in the company, valued at approximately $3,030,386.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 64,986 shares of company stock worth $1,216,988. Corporate insiders own 2.30% of the company’s stock.

A number of large investors have recently modified their holdings of LNTH. California Public Employees Retirement System boosted its stake in Lantheus by 29.2% in the 1st quarter. California Public Employees Retirement System now owns 77,800 shares of the medical equipment provider’s stock worth $973,000 after buying an additional 17,600 shares during the last quarter. Vanguard Group Inc. boosted its stake in Lantheus by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 788,396 shares of the medical equipment provider’s stock worth $9,855,000 after buying an additional 51,590 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in Lantheus in the 1st quarter worth about $3,646,000. Morgan Stanley boosted its stake in Lantheus by 57.2% in the 1st quarter. Morgan Stanley now owns 360,113 shares of the medical equipment provider’s stock worth $4,502,000 after buying an additional 130,992 shares during the last quarter. Finally, Capstone Asset Management Co. acquired a new stake in Lantheus in the 2nd quarter worth about $286,000. 91.95% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Lantheus (LNTH) Rating Lowered to Buy at BidaskClub” was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/lantheus-lnth-rating-lowered-to-buy-at-bidaskclub/1748983.html.

Lantheus Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Receive News & Ratings for Lantheus Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.